Insiders who reported open-market trades in the last 12 months at the companies Redmile Group, LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Colin Walsh - $27.32M in ATTO purchases and sales in the last 12 months
Redmile Group, LLC is a corporate entity, tracked as 10% Owner of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 18 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Redmile Group, LLC submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Redmile Group, LLC been buying or selling stock?
Recorded transactions: 10 open-market purchases ($41.64M) and 9 open-market sales ($20.43M) across all tracked filings.
Redmile Group, LLC is 10% Owner of Attovia Therapeutics, Inc. (ATTO). 18 SEC Form 4 filings on record going back to 2024, most recently on 8 August 2026. Most recent open-market trade: bought $6.80M of ATTO on 8 August 2026. Lifetime open-market purchases: $41.64M. Lifetime open-market sales: $20.43M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Redmile Group, LLC.
InsiderAlpha's records for Redmile Group, LLC go back to 2024: 18 primary Form 4 filings, an average of 6.0 per year. The typical open-market purchase is $4.16M (10 buys totaling $41.64M). The largest single buy on record is $15.00M of ADCT in 2025. Sales side: 9 recorded sales totaling $20.43M, so the filing history runs buy-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
